Discover and read the best of Twitter Threads about #tht2022

Most recents (4)

Join now at #THT2022 as @HFpEF describes the results of the REDUCE HF-LAP II trial: the largest contemporary HFpEF device based trial.

Not the exclusion criteria for patients that may not tolerate a right sided volume load were defined by resting RA pressure, TR severity and PVR
This was a sick population with a median resting PCWP > 18. Meticulous definition of HFpEF with Exercise hemodynamics

The LA strain was quite low in both arms and could that affect who would respond @RBPatelMD?
To the results: as predicted there was no change in incidence of CVD ☠️ btw sham and IASD, but there was also not a difference in 🏥.

What accounts for this result?

This was a sick population overall and wonder if those w/ low LA/RA reservoir affected likelihood to respond
Read 4 tweets
Join now as Dr. Mann gives a keynote on HF in 2022 in the era of SGLT2i #THT2022

“Predicting the future isn’t what it used to be” - Yogi Berra

In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists
Followed by @NirUrielMD talking about the future of HF and pointing out this fantastic paper from @HRRosenblum on a device-based approach to ADHF w/ the DRI2️⃣P2️⃣S approach

Read paper here: ahajournals.org/doi/full/10.11…

@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok
What a whirlwind tour by @GreggWStone on how the sausage gets made with HF device clinical trials

Look at all the factors: critical background on understanding how the evidence forms for the science we apply at the bedside

@mvaduganathan @FudimMarat @vbluml @SJGreene_md
Read 5 tweets
Very insightful discussion on Spectrum of SGLT2-Inhibitor Benefits: Clinical to Symptoms to Quality of Life by @JavedButler1 in #THT2022

@LindenfeldJoa @TheHeartBeat3 @LiviuKlein @HFpEF @RyanTedfordMD @GreggWStone @SKumar_UTHealth @gtsayer @SrihariNaiduMD @purviparwani
📌SGLT2i clinical benefits is seen irrespective of baseline health status

#SGLT2i improve health status and quality of life early and sustained in both patients with #HFrEF and #HFpEF
@JavedButler1
@ShelleyZieroth @SeguraCardio @docbhardwaj @docbhardwaj @KevinShahMD #THT2022
#Canagliflozin Improves Quality of Life in HF Patients in #CHIEF-HF

One of the strengths of CHIEF-HF is the diversity of participants, noting that 14% of patients were Black and 45% were female @JavedButler1 #THT2022 @JamalRanaMD @crfheart @SantosGallegoMD @ShelleyZieroth
Read 4 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!